Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Autoimmune Hepatitis (AIH)

Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory, autoimmune disease in which one’s own immune system attacks healthy, normal liver cells. AIH can be classified into two clinically relevant types, Type 1 and 2, where AIH-1 represents about 80% of AIH, and has a strong female predominance ~ 72% of affected people are female. Type 1- also referred to as the classic type, is typically diagnosed in adulthood. Type 2 autoimmune hepatitis is less common and generally affects girls between the ages of 2 and 14, although it is probably underdiagnosed and underreported.

Thelansis estimated in the US an annual incidence of 1 per 200,000 cases whereas europe estimated 0.8 to 1.9 cases per 10,000 populations.

Autoimmune Hepatitis (AIH) genes are located on the short arm of chromosome 6, within the human leukocyte antigen (HLA) class II region, with particular regard to the ones encoding allelic variants of DRB1.39 AIH-1 susceptibility has been associated with DRB1*0301 and DRB1*040140,41 in white North American and Northern European individuals and to DRB1*0405 and DRB1*0404 in Japan according to literature survey.

Competitive landscape of Autoimmune Hepatitis (AIH) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Autoimmune Hepatitis (AIH) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Autoimmune Hepatitis (AIH) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company                                                     Stage

1        budesonide              Dr. Falk Pharma GmbH                    Phase 3

2        VAY736                   Novartis Pharmaceuticals            Phase 3

3        JKB-122                        TaiwanJ Pharmaceuticals Co.     Phase 2

4        RO7049665                Hoffmann-La Roche                      Phase 2

5        sPIF                                BioIncept LLC                                    Phase 1